136 related articles for article (PubMed ID: 11297498)
1. Vitreous concentration of topically applied brimonidine tartrate 0.2%.
Kent AR; Nussdorf JD; David R; Tyson F; Small D; Fellows D
Ophthalmology; 2001 Apr; 108(4):784-7. PubMed ID: 11297498
[TBL] [Abstract][Full Text] [Related]
2. Vitreous concentration of topically applied brimonidine-purite 0.15%.
Kent AR; King L; Bartholomew LR
J Ocul Pharmacol Ther; 2006 Aug; 22(4):242-6. PubMed ID: 16910864
[TBL] [Abstract][Full Text] [Related]
3. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
4. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%.
Schoenberger SD; Kim SJ; Sheng J; Calcutt MW
JAMA Ophthalmol; 2014 Feb; 132(2):150-4. PubMed ID: 24264034
[TBL] [Abstract][Full Text] [Related]
5. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
6. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes.
Acheampong AA; Shackleton M; John B; Burke J; Wheeler L; Tang-Liu D
Drug Metab Dispos; 2002 Apr; 30(4):421-9. PubMed ID: 11901096
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
PLoS One; 2022; 17(12):e0277313. PubMed ID: 36454807
[TBL] [Abstract][Full Text] [Related]
8. Non-systemic delivery of topical brimonidine to the brain: a neuro-ocular tissue distribution study.
Abdulrazik M; Tamilvanan S; Benita S
J Drug Target; 2006 Dec; 14(10):670-9. PubMed ID: 17162736
[TBL] [Abstract][Full Text] [Related]
9. Formulation effects on ocular absorption of brimonidine in rabbit eyes.
Acheampong AA; Small D; Baumgarten V; Welty D; Tang-Liu D
J Ocul Pharmacol Ther; 2002 Aug; 18(4):325-37. PubMed ID: 12222763
[TBL] [Abstract][Full Text] [Related]
10. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
11. Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445209
[TBL] [Abstract][Full Text] [Related]
12. Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography/mass spectrometric assay.
Acheampong A; Tang-Liu DD
J Pharm Biomed Anal; 1995 Jul; 13(8):995-1002. PubMed ID: 8580159
[TBL] [Abstract][Full Text] [Related]
13. Adrenoceptor agonist poisoning after accidental oral ingestion of brimonidine eye drops.
Hoffmann U; Kuno S; Franke G; Fusch C; Haas JP
Pediatr Crit Care Med; 2004 May; 5(3):282-5. PubMed ID: 15115569
[TBL] [Abstract][Full Text] [Related]
14. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination.
Larsson LI
Arch Ophthalmol; 2001 Apr; 119(4):492-5. PubMed ID: 11296014
[TBL] [Abstract][Full Text] [Related]
15. Effects of brimonidine on aqueous humor dynamics in human eyes.
Toris CB; Gleason ML; Camras CB; Yablonski ME
Arch Ophthalmol; 1995 Dec; 113(12):1514-7. PubMed ID: 7487618
[TBL] [Abstract][Full Text] [Related]
16. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma.
Konstas AG; Stewart WC; Topouzis F; Tersis I; Holmes KT; Stangos NT
Am J Ophthalmol; 2001 Jun; 131(6):729-33. PubMed ID: 11384568
[TBL] [Abstract][Full Text] [Related]
18. Effect of brimonidine tartrate on ocular hemodynamic measurements.
Lachkar Y; Migdal C; Dhanjil S
Arch Ophthalmol; 1998 Dec; 116(12):1591-4. PubMed ID: 9869786
[TBL] [Abstract][Full Text] [Related]
19. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review.
Saylor M; McLoon LK; Harrison AR; Lee MS
Arch Ophthalmol; 2009 Apr; 127(4):402-6. PubMed ID: 19365015
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.
Chen MJ; Chou JC; Hsu WM; Liu JH
J Chin Med Assoc; 2003 May; 66(5):276-81. PubMed ID: 12908569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
